ADVANCED HEPATOCELLULAR CARCINOMA
Clinical trials for ADVANCED HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat liver cancer
Disease control TerminatedThis early-phase trial tests a new treatment called RPCAR01 for people with advanced liver cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein call…
Matched conditions: ADVANCED HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo therapy tackles cancer in HIV patients
Disease control OngoingThis early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
Matched conditions: ADVANCED HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Immune drug plus targeted chemo shows promise for liver cancer in early trial
Disease control OngoingThis early-phase study tests whether combining the immune-boosting drug nivolumab with a procedure that delivers chemotherapy directly to liver tumors (called deb-TACE) is safe for people with advanced liver cancer. Twenty participants will receive the combination, and researcher…
Matched conditions: ADVANCED HEPATOCELLULAR CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New immunotherapy combo shows promise for advanced liver cancer
Disease control OngoingThis study tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. About 111 participants will receive the drugs to see how safe they are and whether they shrink tum…
Matched conditions: ADVANCED HEPATOCELLULAR CARCINOMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Experimental cell infusion targets tough liver tumors
Disease control OngoingThis early-phase study tests a new cell therapy called CT0180 in 21 adults with advanced liver cancer that has not responded to other treatments. The main goals are to check safety, find the best dose, and see how long the cells stay in the body. Participants receive one or more …
Matched conditions: ADVANCED HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New RNA cocktail takes on advanced liver cancer in early trial
Disease control OngoingThis early-phase study tests a new RNA-based drug (MTL-CEBPA) together with two approved immunotherapy drugs (atezolizumab and bevacizumab) in people with advanced liver cancer who have not had prior systemic treatment. The main goals are to find the safest dose and to see how th…
Matched conditions: ADVANCED HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC